Next Article in Journal
Breast Cancer Subtypes Underlying EMT-Mediated Catabolic Metabolism
Next Article in Special Issue
Multivalency Beats Complexity: A Study on the Cell Uptake of Carbohydrate Functionalized Nanocarriers to Dendritic Cells
Previous Article in Journal
Formation of βTC3 and MIN6 Pseudoislets Changes the Expression Pattern of Gpr40, Gpr55, and Gpr119 Receptors and Improves Lysophosphatidylcholines-Potentiated Glucose-Stimulated Insulin Secretion
Previous Article in Special Issue
Nucleic Acid-Based Approaches for Tumor Therapy
Open AccessReview

Targeted Activation of T Cells with IL-2-Coupled Nanoparticles

1
Department of Dermatology, Johannes Gutenberg-University Mainz, 55122 Mainz, Germany
2
Max Planck Institute for Polymer Research, 55128 Mainz, Germany
3
Department of Dermatology, Westfälische Wilhelms-University Münster, 48149 Münster, Germany
*
Author to whom correspondence should be addressed.
Cells 2020, 9(9), 2063; https://doi.org/10.3390/cells9092063
Received: 29 July 2020 / Revised: 24 August 2020 / Accepted: 8 September 2020 / Published: 9 September 2020
(This article belongs to the Special Issue Nanoparticles in Cancer Immunotherapy)
Interleukin-2 (IL-2) is a T cell growth factor particularly required in regulatory T cell maintenance and memory T cell responses. High-dose IL-2 treatment was the first FDA-approved immunotherapy for cancer, while low-dose IL-2 administration has shown promise in allograft rejection and autoimmune and inflammatory diseases. However, its pleiotropic nature and the existence of IL-2 receptors with different binding affinity limit its therapeutic application. For an improved clinical applicability of the cytokine, a targeted receptor assignment must, therefore, be achieved. Nanoparticles allow controlling the location and dose of immunomodulating compounds and to specifically address specific receptors through targeted drug binding. In this review article we discuss the IL-2 biology and current clinical application with regard to nanoparticle-based IL-2-mediated manipulation of T cell responses in autoimmunity, chronic inflammation, and cancer. View Full-Text
Keywords: interleukin-2; nanoparticles; immunotherapy interleukin-2; nanoparticles; immunotherapy
Show Figures

Figure 1

MDPI and ACS Style

Raker, V.K.; Becker, C.; Landfester, K.; Steinbrink, K. Targeted Activation of T Cells with IL-2-Coupled Nanoparticles. Cells 2020, 9, 2063.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop